Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 7/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1370835 | 0.95 | DGAT1 (0.35) | DGAT1MAPTHPGDJAK2JAK1 | |
| SCHEMBL1370838 | 0.94 | DGAT1 (0.34) | DGAT1MAPTPTPN1HPGDJAK2 | |
| SCHEMBL1371408 | 0.91 | DGAT1 (0.33) | DGAT1MAPTHPGDJAK2JAK1 | |
| SCHEMBL1369228 | 0.90 | DGAT1 (0.35) | DGAT1MAPTHPGDJAK2JAK1 | |
| SCHEMBL1369830 | 0.89 | ESRRG (0.37) | DGAT1MAPTHPGD | |
| SCHEMBL14795236 | 0.87 | DGAT1 (0.33) | DGAT1MAPTPTPN1HPGD | |
| SCHEMBL1369229 | 0.86 | DGAT1 (0.34) | DGAT1MAPTHPGDJAK2JAK1 | |
| SCHEMBL1369660 | 0.86 | DYRK1A (0.34) | DGAT1MAPTHPGDJAK2JAK1 | |
| SCHEMBL14795124 | 0.84 | ESRRG (0.42) | DGAT1 | |
| SCHEMBL1370843 | 0.84 | STIM1 (0.33) | DGAT1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155376-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2014-06-05 | — | — | US | disclosed |
| EP-2571880-A1 | PYRROLO [2, 3 - B]PYRAZINE - 7 - CARBOXAMIDE DERIVATIVES AND THEIR USE AS JAK AND SYK INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155376-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | SYK, ZAP70, JAK2 | DGAT1 4772/4885MAPT 3873/4885PTPN1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.